Endocyte

Endocyte (NASDAQ: ECYT) is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana,^[1] a resident of the Purdue Research Park.^[2] In 2011 the company completed successfully an initial public offering (IPO).^[3] As of 2013, the company had 93 employees.^[1] The President and CEO of the company is Ron Ellis.^[1]

Endocyte is advancing the first technology platform for the creation of small molecule drug conjugates (aka SMDCs), which consist of a small molecule linked to a potent drug, and is developing a pipeline of SMDCs together with non-invasive companion imaging agents for cancer, inflammatory diseases and kidney disease (autosomal-dominant polycystic kidney disease/ADPKDor PKD).^[1][4] Endocyte’s lead drug candidate is vintafolide, an investigational targeted cancer therapeutic in late-stage development. In 2012 marketing rights were acquired by Merck for $120 million in an upfront payment and up to $880 million in milestone payments.^[5] Vintafolide is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is expressed on many cancers, such as ovarian cancer, and a potent chemotherapy drug, a derivative of vinblastine.^[1] Endocyte retained rights to the development and commercialization of etarfolatide.^[5] Endocyte’s other preclinical drug candidates also target the folate receptor as well as prostate-specific membrane antigen (PSMA) receptors.^[1] The company was formed based on technology developed by Philip Low (the company's CSO), and Christopher Leamon, Ph.D., the company’s VP of research. This technology is a folic acid-based drug delivery system,^[1] referred to now as folate targeting.^[6] The company is also developing SMDCs with varying drug payloads as well as different ligands for other molecular targets, such as prostate-specific membrane antigen (PMSA) and has also developed, with Bristol-Myers Squibb, an epothilone-folic acid conjugate (BMS-753493), described at a 2008 conference.^[7]

References